Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Regeneron and Sanofi have expanded their antibody collaboration, adding four next-generation long-acting antibodies targeting key interleukins involved in type 2 inflammation. Regeneron will receive $1 billion upfront and potential $7 billion in milestones, sharing development costs and profits equally with Sanofi. This builds on their successful D…